News Headlines Article

HHS to award flu vaccine contracts worth $215 million
Modern Healthcare

HHS said it will award two U.S. companies contracts worth a total of $215 million to develop new seasonal flu vaccines more rapidly. According to the agency, Rockville, Md.-based Novavax has a three-year contract for $97 million that can be extended an additional two years for a total of $179.1 million. Novavax will develop the technology to produce vaccines that use insect cells to express proteins and create viruslike particles that, in turn, stimulate a strong immune response in humans.